Inhibitors of cruzipain and other cysteine proteases
    3.
    发明申请
    Inhibitors of cruzipain and other cysteine proteases 有权
    克鲁替班和其他半胱氨酸蛋白酶抑制剂

    公开(公告)号:US20040138250A1

    公开(公告)日:2004-07-15

    申请号:US10466384

    申请日:2004-01-08

    发明人: Martin Quibell

    CPC分类号: C07D491/04

    摘要: Compounds of general formula (I) or general formula (II) wherein R1, P1, P2, Q, Y, (X)o, (W)n, (V)m, Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therapeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds. 1

    摘要翻译: 其中R 1,P 1,P 2,Q,Y,(X)o,(W)n,(V)m,Z和U的通式(I)或通式(II)的化合物如 说明书是cruzipain和其他半胱氨酸蛋白酶抑制剂的抑制剂,并且可用作治疗剂,例如在恰加斯病或用于验证治疗性靶化合物。

    Fused bicyclic metalloproteinase inhibitors
    6.
    发明申请
    Fused bicyclic metalloproteinase inhibitors 失效
    融合的双环金属蛋白酶抑制剂

    公开(公告)号:US20040034054A1

    公开(公告)日:2004-02-19

    申请号:US10634162

    申请日:2003-08-05

    CPC分类号: C07D495/04 C07D513/04

    摘要: The present invention relates to fused bicyclic metalloproteinase inhibitors of the formula 1 wherein A, B, X, Y, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating arthritis, inflammation, cancer and other disorders.

    摘要翻译: 本发明涉及下式的稠合双环金属蛋白酶抑制剂,其中A,B,X,Y和R 1如说明书中所定义,以及治疗关节炎,炎症,癌症和其它病症的药物组合物和方法。

    Sustained release compositions
    7.
    发明申请
    Sustained release compositions 审中-公开
    持续释放组合物

    公开(公告)号:US20040023987A1

    公开(公告)日:2004-02-05

    申请号:US10297695

    申请日:2002-12-06

    摘要: A composition prepared by containing or blending a physiologically active non-peptide substance and a biodegradable polymer having two or more carboxylic groups at its end or a salt thereof features: (1) larger content of the physiologically active non-peptide substance can be contained, as well as release of the same can be controlled or accelerated, whereby secure pharmaceutical effect is achieved; (2) when the physiologically active non-peptide substance causes subcutaneous stimulation, an activity of canceling the stimulation by strongly acidic group at its end is expected; and (3) high glass transition point and high stability.

    摘要翻译: 通过含有生理活性非肽物质和在其末端具有两个或更多个羧基的可生物降解的聚合物或其盐来制备的组合物的特征在于:(1)可以含有较大的生理活性非肽物质含量, 可以控制或加速其释放,从而实现安全的药效; (2)当生理活性非肽物质引起皮下刺激时,预期其末端强酸性基团的刺激消除活性; 和(3)高玻璃化转变点和高稳定性。